Pirlindole is a reversible inhibitor of monoamine oxidase A (RIMA) which was developed and is used in Russia as an antidepressant. It is structurally and pharmacologically related to metralindole. Pirlindole is approved in some European and non-European countries for the treatment of depression. Pirlindole has an absolute bioavailability of between 20 and 30% due to an extensive first-pass effect. orally , the Tmax varies between 2.5 and 6 h in the rat and 0.8 and 2 h in the dog. References: Macedo A, Leiria E, Filipe A. Pirlindole in the treatment of depression: a meta-analysis. Clin Drug Investig. 2011;31(1):61-71. doi: 10.2165/11586690-000000000-00000. PubMed PMID: 21053988.

纯度：≥98%

CAS：60762-57-4